|Publication Type||Government Report|
|Year of Publication||2016|
|Authors||Services, Department of Health|
|Selection||Grey literature, healthcare policy; Key & Foundational; Mat and su disorders|
This final rule increases access to medication-assisted treatment (MAT) with buprenorphine and the combination buprenorphine/naloxone in the office-based setting as authorized under the United States Code. The rule also includes requirements to ensure that patients receive the full array of services that comprise evidence-based MAT and minimize the risk that the medications provided for treatment are misused or diverted.
|Additional||More about this reference (PDF - 0.48 MB)|
|Note||This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.|